Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Den Haag, Netherlands Clinical Trials

A listing of Den Haag, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (119) clinical trials

Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases

Study population: patients with painful spinal metastases from solid tumors without spinal cord compression or cord instability. Objective: This study will test the hypothesis that stereotactic radiotherapy gives a better and longer lasting reduction of pain, local control and therewith a better quality of life. This in order to optimize ...

Phase

0.0 miles

Learn More »

DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.

Rationale: Iliofemoral deep venous thrombosis (IFDVT) is associated with significant post thrombotic morbidity. The presence of both obstruction and reflux significantly increases the chances for development of post-thrombotic syndrome (PTS). Early thrombolysis may reduce the incidence of PTS as compared to treatment with conventional anticoagulant medication alone. Improvement of the ...

Phase

0.0 miles

Learn More »

Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

The trial consists of two cohorts: Cohort A, patients without an indication for OAC prior to TAVI. Cohort B, patients with an indication for OAC prior to TAVI (eg. atrial fibrillation, mechanic mitral valve prosthesis).

Phase

0.0 miles

Learn More »

Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

This trial aims to improve the strength of the MRD ( minimal residual disease) response as defined by achieving complete MRD negative response (ie, < 10^-4) after the first consolidation phase including blinatumomab.

Phase

0.0 miles

Learn More »

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC BCL2 and/or BCL6 Rearranged HGBL

The dismal prognosis of DH-DLBCL patients following standard therapy with R-CHOP (overall survival at 2 years 35% for MYC+ vs 61% for MYC- patients) justifies upfront new treatment approaches. Attempts have been made to improve prognosis of DH-DLBCL patients with intensified chemotherapy schemes like DA-EPOCH-R, standard treatment of Burkitt lymphoma ...

Phase

0.0 miles

Learn More »

Reducing Dexamethasone Around Docetaxel Infusion

The manufacturer recommends two different regimens of prophylactic dexamethasone to prevent hypersensitivity and fluid retention reactions caused by docetaxel: a 3-day regime of dexamethasone 8mg twice a day starting the day before chemotherapy for breast cancer and for prostate cancer 3 times 8mg dexamethasone on the day of docetaxel infusion, ...

Phase

0.0 miles

Learn More »

OPTIMIZE IDE for the Treatment of ACS

Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length with a reference vessel ...

Phase N/A

0.0 miles

Learn More »

Seizure Treatment in Glioma

Currently, treatment of glioma patients with a specific anti-epileptic drug (AED) mainly depends on the physicians' preference, as there is no robust evidence from randomized controlled trials supporting the use of one specific anticonvulsant above the other in glioma patients. Levetiracetam and valproic acid are the most commonly used AEDs ...

Phase

0.0 miles

Learn More »

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with ...

Phase

0.0 miles

Learn More »